Hansa Biopharma AB (HNSBF)
2.93
0.00 (0.00%)
USD |
OTCM |
Sep 20, 16:00
Hansa Biopharma 1 Year Total Returns (Daily): -25.45% for Sept. 19, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
Date | Value |
---|---|
September 19, 2024 | -25.45% |
September 18, 2024 | -25.45% |
September 17, 2024 | -25.45% |
September 16, 2024 | -25.45% |
September 13, 2024 | -25.45% |
September 12, 2024 | -25.45% |
September 11, 2024 | -25.45% |
September 10, 2024 | -25.45% |
September 09, 2024 | -25.45% |
September 06, 2024 | -25.45% |
September 05, 2024 | -25.45% |
September 04, 2024 | -25.45% |
September 03, 2024 | -25.45% |
August 30, 2024 | -25.45% |
August 29, 2024 | -25.45% |
August 28, 2024 | -38.38% |
August 27, 2024 | -38.38% |
August 26, 2024 | -38.38% |
August 23, 2024 | -38.38% |
August 22, 2024 | -38.38% |
August 21, 2024 | -38.38% |
August 20, 2024 | -38.38% |
August 19, 2024 | -38.38% |
August 16, 2024 | -38.38% |
August 15, 2024 | -38.38% |
Date | Value |
---|---|
August 14, 2024 | -38.38% |
August 13, 2024 | -38.38% |
August 12, 2024 | -38.38% |
August 09, 2024 | -38.38% |
August 08, 2024 | -38.38% |
August 07, 2024 | -38.38% |
August 06, 2024 | -38.38% |
August 05, 2024 | -38.38% |
August 02, 2024 | -38.38% |
August 01, 2024 | -38.38% |
July 31, 2024 | -38.38% |
July 30, 2024 | -44.66% |
July 29, 2024 | -44.66% |
July 26, 2024 | -44.66% |
July 25, 2024 | -44.66% |
July 24, 2024 | -44.66% |
July 23, 2024 | -44.66% |
July 22, 2024 | -44.66% |
July 19, 2024 | -44.66% |
July 18, 2024 | -44.66% |
July 17, 2024 | -44.66% |
July 16, 2024 | -44.66% |
July 15, 2024 | -44.66% |
July 12, 2024 | -44.66% |
July 11, 2024 | -44.66% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-76.81%
Minimum
Dec 17 2019
112.5%
Maximum
Oct 07 2020
-27.58%
Average
-43.65%
Median
Mar 14 2024
1 Year Total Returns (Daily) Benchmarks
Abliva AB | -- |
Karolinska Development AB | 0.00% |
Calliditas Therapeutics AB | 144.2% |
Oncopeptides AB | -- |
BioInvent International AB | 0.00% |